
Eli Lilly and Company, Johnson & Johnson, AbbVie, Merck & Co., Inc., Gilead Sciences, Pfizer, and McKesson are the seven Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks are shares of companies that research, develop, manufacture, or sell medicines and other drug products. For investors, their value can be influenced by factors such as drug-trial results, regulatory approvals, patent expirations, and sales performance. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of NYSE LLY traded down $4.72 during trading on Friday, hitting $1,346.40. 3,539,886 shares of the company traded hands, compared to its average volume of 3,110,726. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,475.25. The company has a 50-day moving average price of $1,268.06 and a 200-day moving average price of $1,119.25. The firm has a market capitalization of $1.27 trillion, a P/E ratio of 43.70, a P/E/G ratio of 1.61 and a beta of 0.40. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17.
Read Our Latest Research Report on LLY
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Shares of JNJ traded up $3.40 during trading hours on Friday, hitting $270.54. The stock had a trading volume of 11,918,705 shares, compared to its average volume of 7,542,975. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The firm has a market cap of $651.27 billion, a P/E ratio of 40.99, a P/E/G ratio of 2.72 and a beta of 0.22. The company’s fifty day simple moving average is $267.53 and its 200 day simple moving average is $250.98. Johnson & Johnson has a 12-month low of $199.90 and a 12-month high of $290.25.
Read Our Latest Research Report on JNJ
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
AbbVie stock traded up $2.65 during midday trading on Friday, reaching $286.19. The stock had a trading volume of 8,754,855 shares, compared to its average volume of 5,124,685. The stock’s 50-day simple moving average is $278.98 and its 200 day simple moving average is $242.55. AbbVie has a twelve month low of $190.75 and a twelve month high of $302.93. The stock has a market capitalization of $505.88 billion, a PE ratio of 49.26, a price-to-earnings-growth ratio of 1.30 and a beta of 0.20.
Read Our Latest Research Report on ABBV
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
NYSE:MRK traded up $0.75 on Friday, hitting $133.56. 15,606,219 shares of the stock were exchanged, compared to its average volume of 9,189,798. The stock has a fifty day moving average of $145.28 and a 200-day moving average of $129.29. The stock has a market cap of $329.26 billion, a PE ratio of 137.69, a PEG ratio of 6.13 and a beta of 0.13. The company has a current ratio of 1.35, a quick ratio of 1.14 and a debt-to-equity ratio of 1.11. Merck & Co., Inc. has a fifty-two week low of $95.36 and a fifty-two week high of $156.92.
Read Our Latest Research Report on MRK
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Shares of NASDAQ GILD traded down $0.20 during midday trading on Friday, hitting $166.33. The stock had a trading volume of 7,554,884 shares, compared to its average volume of 6,363,988. The company has a market capitalization of $206.30 billion, a price-to-earnings ratio of -52.64 and a beta of 0.35. Gilead Sciences has a 1-year low of $116.88 and a 1-year high of $176.58. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84. The company has a fifty day moving average price of $157.26 and a 200 day moving average price of $142.46.
Read Our Latest Research Report on GILD
Pfizer (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Shares of NYSE:PFE traded down $0.13 during trading on Friday, reaching $27.41. 38,282,328 shares of the stock were exchanged, compared to its average volume of 37,345,556. The firm’s 50-day moving average price is $28.82 and its 200 day moving average price is $27.03. The firm has a market cap of $156.25 billion, a price-to-earnings ratio of 39.16, a price-to-earnings-growth ratio of 1.80 and a beta of 0.31. Pfizer has a 12-month low of $23.62 and a 12-month high of $31.44. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.10 and a current ratio of 1.42.
Read Our Latest Research Report on PFE
McKesson (MCK)
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
NYSE MCK traded up $7.15 during mid-day trading on Friday, hitting $1,069.31. The company’s stock had a trading volume of 869,451 shares, compared to its average volume of 710,413. The firm has a market capitalization of $123.46 billion, a P/E ratio of 27.50, a price-to-earnings-growth ratio of 1.81 and a beta of 0.27. McKesson has a 52-week low of $723.68 and a 52-week high of $1,121.50. The stock’s fifty day simple moving average is $974.65 and its two-hundred day simple moving average is $880.71.
Read Our Latest Research Report on MCK
Featured Stories
- MarketBeat’s Top Five Stocks to Own in November 2026
- Growing Pains Versus Growth: Is BJ’s Wholesale Club a Buying Opportunity?
- Keysight Technologies: The Tollbooth on the Technology Superhighway
- Zscaler Got a Boost From Palo Alto, But Now It Has to Deliver.
- Bargain Hunting: Why Off-Price Retail Is Winning
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
